BMY - Acceleron Heads Toward Commercial Success

Acceleron (XLRN) is about to become a commercial stage biotechnology pharmaceutical company because it will soon begin receiving royalties from sales of its recently-approved lead drug. It serves as an example of the need for patient investing strategies in clinical-stage pharmaceutical companies, where it is years between when a potential drug begins human trials and receive regulator approval for commercial sales. Investor sentiment may waver quite a bit over this period of time. In the case of Acceleron its highest stock price was in December 2018 at $59.59, its 52-week high. But it